Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul-Aug;39(4):1113-1118.
doi: 10.12669/pjms.39.4.7353.

Efficacy and safety profile of Glucagon-Like Peptide-1 Receptor Agonist in obese Type-2 diabetes patients from a private institution in Karachi

Saeeda Fouzia Qasim  1 , Tasnim Ahsan  2 , Saima Ghaus  3 , Paras Imran  4
Affiliations

Efficacy and safety profile of Glucagon-Like Peptide-1 Receptor Agonist in obese Type-2 diabetes patients from a private institution in Karachi

Saeeda Fouzia Qasim et al. Pak J Med Sci. 2023 Jul-Aug.

Abstract

Objective: To assess the effectiveness of GLP-1RAs in managing obese T2DM patients.

Methods: This prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021. A total of 97 obese individuals >16 years of age with T2DM and IGT were initially enrolled, and 81 patients who showed up for the follow-up were prescribed one of the three GLP-1RAs available in Pakistan.

Results: Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin. The mean age of the enrolled patients was 49.21(12.44) years, and there was female predominance (55.6%). Overall, there was a significant weight and BMI reduction among the patients treated with either of the GLP-1RAs (P<.01). Furthermore, significant glycemic control was observed in all three groups after the treatment. The Dulaglutide group demonstrated a more significant reduction of HbA1c compared to Liraglutide group, which showed more pronounced weight and BMI reduction. Nevertheless, this class of medications was well-tolerated, with nausea being the most often reported side effect.

Conclusion: GLP-1RAs showed favorable weight and HbA1c reduction among patients of all three treatment groups.

Keywords: Diabetes Mellitus; GLP-1RA; Glycemic control; HbA1c; Obesity.

PubMed Disclaimer

Figures

Fig.1
Fig.1
Study flow diagram.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas:Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. J Diabetes Res. 2022;183:109119. doi:10.1016/j.diabres.2021.109119. - PMC - PubMed
    1. 33m Pakistani adults living with diabetes:Report. The News. 2021. [Updated November 13, 2021]. Available at: https://www.thenews.com.pk/print/908338-33m-pakistani-adults-living-with... .
    1. Marso SP, Baeres FM, Bain SC, Goldman B, Husain M, Nauck MA, et al. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure. J Am Coll Cardiol. 2020;75(10):1128–1141. doi:10.1016/j.jacc.2019.12.063. - PubMed
    1. Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, et al. Antidiabetic therapy in the treatment of nonalcoholic steatohepatitis. Int J Mol Sci. 2020;21(6):1907. doi:10.3390/ijms21061907. - PMC - PubMed
    1. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a Weekly IN cretin in D iabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20(1):42–49. doi:10.1111/dom.13028. - PubMed

LinkOut - more resources